Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)

• Arnt V. Kristen ,

  * E-mail: Arnt_Kristen@med.uni-heidelberg.de

  Affiliation Amyloidosis Center, Department of Cardiology, Heidelberg University, Heidelberg, Germany

  ⨯
• Mathew S. Maurer,

  Affiliation Center for Advanced Cardiac Care, Columbia University Medical Center, New York, New York, United States of America

  ⨯
• Claudio Rapezzi,

  Affiliation Institute of Cardiology, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy

  ⨯
• Rajiv Mundayat,

  Affiliation Pfizer Inc., New York, New York, United States of America

  ⨯
• Ole B. Suhr,

  Affiliation Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden

  ⨯
• Thibaud Damy,

  Affiliation Amyloidosis Network, Department of Cardiology, CHU Henri Mondor, Creteil, France

  ⨯
• on behalf of the THAOS investigators

  ¶A full list of THAOS investigators is provided in the Acknowledgments.

  ⨯